NCT01351480View on ClinicalTrials.gov

Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients

PHASE3CompletedINTERVENTIONAL

Enrollment

34

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

January 31, 2014

Study Completion Date

April 30, 2014

Conditions

Rheumatoid Arthritis

Interventions

BIOLOGICAL

abatacept

Abatacept administered SC weekly at 125 mg dose

Trial Locations (1)

33180

Arthritis & Rheumatic Disease Specialties Research, Aventura

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Arthritis & Rheumatic Disease Specialties Research

OTHER

NCT01351480 - Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients | Biotech Hunter | Biotech Hunter